Cargando…

SNRPB promotes cell cycle progression in thyroid carcinoma via inhibiting p53

Papillary thyroid carcinoma (PTC) accounts for more than 80% of all thyroid carcinoma cases. Small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB) has been indicated to be carcinogenic in several cancers; however, its function and mechanism in PTC are unclarified. Real time quantitative poly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Yan, Li, Xin, Jiang, Wenlei, Tang, Jindan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579862/ https://www.ncbi.nlm.nih.gov/pubmed/36329787 http://dx.doi.org/10.1515/med-2022-0531

Ejemplares similares

SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26
por: Liu, Nianli, et al.
Publicado: (2019)

lncRNA RUNDC3A-AS1 Regulates Proliferation and Apoptosis of Thyroid Cancer Cells via the miR-151b/SNRPB Axis
por: Deng, Yan, et al.
Publicado: (2022)

SNRPB-mediated RNA splicing drives tumor cell proliferation and stemness in hepatocellular carcinoma
por: Zhan, Yu-Ting, et al.
Publicado: (2020)

The oncogenic role of SNRPB in human tumors: A pan-cancer analysis
por: Wu, Juan, et al.
Publicado: (2022)

Snrpb is required in murine neural crest cells for proper splicing and craniofacial morphogenesis
por: Alam, Sabrina Shameen, et al.
Publicado: (2022)

Disrupted auto-regulation of the spliceosomal gene SNRPB causes cerebro–costo–mandibular syndrome
por: Lynch, Danielle C., et al.
Publicado: (2014)

Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma
por: Correa, Bruna R., et al.
Publicado: (2016)

The Core Splicing Factors EFTUD2, SNRPB and TXNL4A Are Essential for Neural Crest and Craniofacial Development
por: Park, Byung-Yong, et al.
Publicado: (2022)

PRIM2 Promotes Cell Cycle and Tumor Progression in p53-Mutant Lung Cancer
por: Wang, Taoyuan, et al.
Publicado: (2022)

Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression
por: Sachweh, M C C, et al.
Publicado: (2013)

Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner
por: Wang, Jiahui, et al.
Publicado: (2022)

CACYBP knockdown inhibits progression of prostate cancer via p53
por: Li, Qiang, et al.
Publicado: (2022)

MicroRNA-92a Promotes Cell Proliferation in Cervical Cancer via Inhibiting p21 Expression and Promoting Cell Cycle Progression
por: Su, Zhiying, et al.
Publicado: (2017)

Long Noncoding RNA LINC00467 Promotes Glioma Progression through Inhibiting P53 Expression via Binding to DNMT1
por: Zhang, Yin, et al.
Publicado: (2020)

p53 suppresses carcinoma progression by inhibiting mTOR pathway activation
por: Akeno, Nagako, et al.
Publicado: (2014)

Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas
por: Moreno, Carlos S., et al.
Publicado: (2007)

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma
por: Yu, Sifan, et al.
Publicado: (2019)

D133P53, directly transactivated by p53, prevents p53-mediated apoptosis without inhibiting p53-mediated cell cycle arrest
por: Aoubala, M, et al.
Publicado: (2010)

YAP1 and P53 Expression in Papillary Thyroid Carcinoma
por: Abdelhafez, Dalia Nabil, et al.
Publicado: (2023)

TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination
por: Chen, Jia-xin, et al.
Publicado: (2021)

RPL15 promotes hepatocellular carcinoma progression via regulation of RPs-MDM2-p53 signaling pathway
por: Shi, Rui, et al.
Publicado: (2022)

C23 promotes tumorigenesis via suppressing p53 activity
por: Li, Qun, et al.
Publicado: (2016)

Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation
por: Zhang, Wei, et al.
Publicado: (2023)

HnRNPL promotes Wilms tumor progression by regulating the p53 and Bcl2 pathways
por: Luo, Xin, et al.
Publicado: (2019)

Inhibition of p53 inhibitors: progress, challenges and perspectives
por: Sanz, Gema, et al.
Publicado: (2019)

IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma
por: Zhang, Le, et al.
Publicado: (2019)

EZH2-Mediated microRNA-375 Upregulation Promotes Progression of Breast Cancer via the Inhibition of FOXO1 and the p53 Signaling Pathway
por: Guan, Xin, et al.
Publicado: (2021)

Genetic Alterations in Thyroid Tumor Progression: Association with p53 Gene Mutations
por: Ito, Takashi, et al.
Publicado: (1993)

SPC25 may promote proliferation and metastasis of hepatocellular carcinoma via p53
por: Chen, Fengjuan, et al.
Publicado: (2020)

BRD7 inhibits tumor progression by positively regulating the p53 pathway in hepatocellular carcinoma
por: Chen, Chang-Long, et al.
Publicado: (2021)

Correction to: IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma
por: Zhang, Le, et al.
Publicado: (2019)

Reactivation of p53 via MDM2 inhibition
por: Kim, E S, et al.
Publicado: (2015)

Hsa-MiR-590-3p Promotes the Malignancy Progression of Pancreatic Ductal Carcinoma by Inhibiting the Expression of p27 and PPP2R2A via G1/S Cell Cycle Pathway
por: Shi, Xiaoyang, et al.
Publicado: (2020)

p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection
por: Lee, E J, et al.
Publicado: (2003)

PRMT5 is required for cell-cycle progression and p53 tumor suppressor function
por: Scoumanne, A., et al.
Publicado: (2009)

p53 Gene Mutations Associated with Anaplastic Transformation of Human Thyroid Carcinomas
por: Nakamura, Tsutomu, et al.
Publicado: (1992)

Inactivation of the p53 Gene Is not Required for Tumorigenesis of Medullary Thyroid Carcinoma or Pheochromocytoma
por: Yana, Ikuo, et al.
Publicado: (1992)

The Role of p53 in Progression of Cutaneous Squamous Cell Carcinoma
por: Piipponen, Minna, et al.
Publicado: (2021)

DBC1 Regulates p53 Stability via Inhibition of CBP-Dependent p53 Polyubiquitination
por: Akande, Oluwatoyin E., et al.
Publicado: (2019)

Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism
por: Zhang, Qingyu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gl2ehpj5g3cvnl27b8rr4jjcto